Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Inclusion Criteria: * Patients with histologic proof of adenocarcinoma of the prostate and must have failed conventional hormonal therapy. * Patients must have osteoblastic bone metastases. At least one osteoblastic lesion must be documented by plain film. Patients with mixed or osteolytic bone metastases must have a biopsy to exclude histologic variants of prostate cancer or metastasis from another primary (for phase II only). * Patients must have evidence of progression of disease as demonstrated by 2 consecutive rise in PSA (an absolute change of at least 1 ng/mL) over 4 weeks. * Patients on flutamide, nilutamide, or bicalutamide should be discontinued from flutamide or nilutamide and bicalutamide for at least 4 weeks and 8 weeks, respectively. * Patients must have an expected survival of at least three months and a Zubrod performance status of \< 2 (Zubrod scale; Appendix B). * Patients may receive no concurrent chemotherapy or immunotherapy. * Patients must have castrate serum testosterone levels (\< 30 ng/dl). For patients who are medically castrated, lutenizing hormone releasing hormone analog must continue to maintain testicular suppression. * Patients must have adequate bone marrow function defined as an absolute peripheral granulocyte count of \> 1,500/mm3 and platelet count of \> 100,000/mm3; adequate hepatic function defined with a bilirubin of \< 1.5 mg% and SGOT (AST) \< 2X the upper limits of normal; adequate renal function defined as serum creatinine clearance \> 40 cc/min (measured or calculated). * Patients must be \>= 18 years old. * Patients may have received oral EMP or no more than one cytotoxic therapy. * Patients must sign a written informed consent form prior to treatment. Exclusion Criteria: * Patients with severe intercurrent infection. * Patients with prior exposure to Taxol. * Patients whose tumors contain small cell or sarcomatoid elements. * Patients with evidence of conduction block or active myocardial ischemia on ECG. * Patients with a history of prior malignancy (except noninvasive cutaneous carcinoma). * Patients with a history of thromboembolism.